Market Overview

UPDATE: Stifel Downgrades Geron from Hold to Sell

Related GERN
Morning Market Movers
Midday Gainers From November 14: Geron, Pandora Media, Bitauto, IAMGOLD

Stifel Nicolaus' Brian Klein downgraded shares of Geron (NASDAQ: GERN) from Hold to Sell in an intraday research note.

Related to Imetelstat rests trial, the analyst said, "While management states that this is the most expedited way to derive the clinical data necessary for future company-sponsored trials, we view this development plan as flawed and sluggish." Klein believes the company should "initiate a parallel Phase 1 study of Imetelstat in myeloid leukemias in 2013, including MDS and AML, in order to provide independent confirmation of the findings from the IST, as well as to broaden the safety and efficacy database for Imetelstat in these indications. However, given management's current strategy, we have reservations on the development plan for Imetelstat..."

Shares of Geron are down nearly 10 percent to around $1.28 at last check.

Latest Ratings for GERN

DateFirmActionFromTo
Jun 2014MLV & Co.UpgradesHoldBuy
Mar 2014NeedhamDowngradesBuyHold
Mar 2014MLV & Co.DowngradesBuyHold

View More Analyst Ratings for GERN
View the Latest Analyst Ratings

Posted-In: Downgrades Analyst Ratings

 

Related Articles (GERN)

Around the Web, We're Loving...

Get Benzinga's Newsletters